Vincerx Pharma Reports Third Quarter 2024 Financial Results
November 12, 2024 09:00 ET
|
Vincerx Pharma, Inc.
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed...
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
October 07, 2024 16:05 ET
|
Vincerx Pharma, Inc.
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™...
Vincerx Pharma Reports Second Quarter 2024 Financial Results
August 08, 2024 16:30 ET
|
Vincerx Pharma, Inc.
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected...
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:15 ET
|
Vincerx Pharma, Inc.
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug...
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
April 26, 2024 00:27 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
April 25, 2024 16:01 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 08, 2024 16:30 ET
|
Vincerx Pharma, Inc.
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 01, 2024 08:00 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
March 29, 2024 15:20 ET
|
Vincerx Pharma, Inc.
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:31 ET
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...